Migraine Drug Developer CoLucid Slashes IPO Target
Venture capital-backed CoLucid Pharmaceuticals Inc. trimmed terms for its anticipated initial public offering Tuesday, shrinking the migraine treatment developer's expected offering size to just $55 million....To view the full article, register now.
Already a subscriber? Click here to view full article